GlobeNewswire: Precipio, Inc. Contains the last 10 of 177 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:05:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/25/2852027/0/en/Precipio-Announces-Year-end-2023-Shareholder-Update-Call.html?f=22&fvtc=4&fvtv=43907Precipio Announces Year end 2023 Shareholder Update Call2024-03-25T21:00:00Z<![CDATA[Conference Call to be held on April 1st, 2024 at 5:00 PM EDT Conference Call to be held on April 1st, 2024 at 5:00 PM EDT]]>https://www.globenewswire.com/news-release/2024/02/13/2828403/0/en/Precipio-to-Report-15-2M-for-FY-2023-unaudited-Revenues-an-increase-of-60-YoY.html?f=22&fvtc=4&fvtv=43907Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY2024-02-13T15:00:00Z<![CDATA[Company continues to make strides towards breakeven Company continues to make strides towards breakeven]]>https://www.globenewswire.com/news-release/2024/02/06/2824486/0/en/Precipio-and-Cardinal-Health-Sign-Distribution-Agreement-for-its-HemeScreen-Portfolio-of-Molecular-assays-for-Cancer.html?f=22&fvtc=4&fvtv=43907Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer2024-02-06T15:00:00Z<![CDATA[NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.]]>https://www.globenewswire.com/news-release/2024/01/23/2814262/0/en/Precipio-s-Q4-2023-Cash-Burn-From-Operations-unaudited-drops-below-100K-for-the-full-quarter.html?f=22&fvtc=4&fvtv=43907Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter2024-01-23T15:00:00Z<![CDATA[Results clearly demonstrate the business’s ability to reach breakeven in the near future Results clearly demonstrate the business’s ability to reach breakeven in the near future ]]>https://www.globenewswire.com/news-release/2024/01/17/2810905/0/en/Precipio-Signs-Distribution-Agreement-For-IV-Cell-and-HemeScreen-in-Japan.html?f=22&fvtc=4&fvtv=43907Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan2024-01-17T15:30:00Z<![CDATA[First order for IV-Cell placed by Major Japanese Laboratory First order for IV-Cell placed by Major Japanese Laboratory]]>https://www.globenewswire.com/news-release/2024/01/02/2802710/0/en/Precipio-Announces-Christina-Valauri-joins-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=43907Precipio Announces Christina Valauri joins the Board of Directors2024-01-02T14:00:00Z<![CDATA[Douglas Fisher, MD will step down as Director, and remain as a board observer Douglas Fisher, MD will step down as Director, and remain as a board observer]]>https://www.globenewswire.com/news-release/2023/12/14/2796729/0/en/Precipio-Management-Shares-Thoughts-on-2023-and-Looks-Ahead-To-2024.html?f=22&fvtc=4&fvtv=43907Precipio Management Shares Thoughts on 2023, and Looks Ahead To 20242023-12-14T21:30:00Z<![CDATA[NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and reflections looking back at 2023, and forward to 2024.]]>https://www.globenewswire.com/news-release/2023/11/16/2782289/0/en/Precipio-Announces-Q3-2023-Shareholder-Update-Call.html?f=22&fvtc=4&fvtv=43907Precipio Announces Q3-2023 Shareholder Update Call2023-11-16T22:00:00Z<![CDATA[Conference Call to be held on November 20th, 2023 at 5:00 PM EST Conference Call to be held on November 20th, 2023 at 5:00 PM EST]]>https://www.globenewswire.com/news-release/2023/10/18/2762417/0/en/Precipio-to-Report-4-5M-Q3-2023-Revenues-Double-From-Q3-2022.html?f=22&fvtc=4&fvtv=43907Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-20222023-10-18T13:00:00Z<![CDATA[28% Revenue Increase Is Major Step Toward Company Breakeven 28% Revenue Increase Is Major Step Toward Company Breakeven]]>https://www.globenewswire.com/news-release/2023/10/03/2753820/0/en/Precipio-s-Q3-Cash-Burn-From-Operations-unaudited-Declines-59-YoY-from-2-5M-in-Q3-2022-to-approximately-1M-in-Q3-2023.html?f=22&fvtc=4&fvtv=43907Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-20232023-10-03T14:00:00Z<![CDATA[Company anticipates current cash levels sufficient to reach breakeven Company anticipates current cash levels sufficient to reach breakeven]]>